Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1070770?
NBI-1070770 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Major Depressive Disorder. According...
Data Insights
NBI-1070770 by Neurocrine Biosciences for Major Depressive Disorder: Likelihood of Approval
NBI-1070770 is under clinical development by Neurocrine Biosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData,...